CD274 and neoplasm: Novel ICP receptors, which include programmed death 1 (PD-1) and its ligand (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), are shown to suppress T cells presented at the tumor site [10, 11].